Clinuvel Pharmaceuticals Limited (CUVL)
Nasdaq: CUVL · American Depositary Receipts · filing with the SEC since 2004
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20268 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Clinuvel Pharmaceuticals Limited’s names, not what it holds today.
Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
12
since 2001, to Dec 31, 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
CLINUVEL PHARMACEUTICALS LIMITED its own name
AU, as the owner printed on each patent
9 published
Clinuvel Pharmaceuticals Limited its own name
named as the applicant on its applications, in AU
3 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Apr 11, 2023 | 11,622,994 | Therapy for vitiligo | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
| Dec 8, 2020 | 10,857,208 | Methods of inducing melanogenesis in a subject | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
| Sep 18, 2018 | 10,076,555 | Methods of inducing melanogenesis in a subject | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
| Oct 31, 2017 | 9,801,924 | Therapy for vitiligo | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
| May 24, 2016 | 9,345,911 | Methods of inducing melanogenesis in a subject | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
| Oct 29, 2013 | 8,569,234 | Compositions and methods for including melanogenesis in a subject | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
| Dec 18, 2012 | 8,334,265 | Method of treatment of photodermatoses | Organic fine chemistry | CLINUVEL PHARMACEUTICALS LIMITED |
| Jun 29, 2010 | 7,745,408 | Method of inducing melanogenesis in humans with MC1R variant alleles | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Aug 6, 2020 | 2020/0246436 | ALPHA-MSH ANALOGUES USED IN THE TREATMENT OF XERODERMA PIGMENTOSUM | Pharmaceuticals | Clinuvel Pharmaceuticals Limited |
| Dec 20, 2018 | 2018/0360919 | METHODS OF INDUCING MELANOGENESIS IN A SUBJECT | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED · patent 10,857,208 granted from it |
| Jan 11, 2018 | 2018/0008676 | THERAPY FOR VITILIGO | Pharmaceuticals | Clinuvel Pharmaceuticals Limited · patent 11,622,994 granted from it |
| Aug 18, 2016 | 2016/0235819 | METHODS OF INDUCING MELANOGENESIS IN A SUBJECT | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED · patent 10,076,555 granted from it |
| Dec 26, 2013 | 2013/0344153 | METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS | Pharmaceuticals | Clinuvel Pharmaceuticals Limited |
| Aug 8, 2013 | 2013/0203670 | Therapy For Vitiligo | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED · patent 9,801,924 granted from it |
| Oct 27, 2011 | 2011/0263508 | Compositions and methods for including melanogenesis in a subject | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED · patent 8,569,234 granted from it |
| Jun 2, 2011 | 2011/0130705 | THERAPY FOR VITILIGO | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
| May 13, 2010 | 2010/0120668 | METHOD OF TREATMENT OF PHOTODERMATOSES | Organic fine chemistry | CLINUVEL PHARMACEUTICALS LIMITED · patent 8,334,265 granted from it |
| May 6, 2010 | 2010/0113337 | METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS | Pharmaceuticals | CLINUVEL PHARMACEUTICALS LIMITED |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.